The NZ Herald reports….

Mr Dunne said the need for “fine-tuning” was inevitable, given that medical cannabis was a new policy area for the Ministry of Health and wider medical profession.

“The guidelines were set up at my request following the Alex Renton case in 2015, so far the only case where ministerial approval was granted, following an application from Mr Renton’s treating clinicians to administer the restricted product Elixinol,” Mr Dunne said.

He said the guidelines were more recently applied to an application for medical cannabis made on behalf of former Council of Trade Unions head Helen Kelly, but subsequently withdrawn by her oncologist before any ministerial decision was required.

“While I am satisfied that on the whole the guidelines are sound, they were prepared as guidance only. They allow for flexibility across different clinical situations, and are certainly not set in stone as some have claimed.

“Nonetheless, some further review would be beneficial and I have asked officials to undertake further consideration of them. I am not ruling out seeking external input into this review process.”

Mr Dunne said he would be discussing these issues in Canberra next week at the Australian Drug Foundation’s National Drug Summit.

Read the full report at